Dr. Lepak is a recent graduate of the fellowship program and T32 training grant. His research pursuits are in performing and translating antimicrobial pharmacodynamic (PD) studies (both in vivo animal models and patient level data) to optimize therapy against numerous pathogens. Specifically, his current research focus is on the optimization of antifungal therapy for invasive aspergillosis employing an in vivo animal model and the examination of clinical trial data in patients with disseminated candidiasis to determine PD targets for numerous antifungal agents. The lab also studies the PD of antimicrobial therapy against isolates with reduced susceptibility (such as MRSA or MDR GNR) to guide optimal dosing designs for difficult to treat infections and susceptibility break point determination. An additional area of study is antimicrobial drug development using in vivo animal models.
Search for Alexander Lepak's literature abstracts on PubMed